All In Biotech

Drug Trial Radar · NCT01370265

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

Quantification of Myocardial Blood Flow by Positron Emission Tomography and N-13 Ammonia During Regadenoson vs Adenosine Stress

Last checked: Nov 21, 2026Latest source record: Sep 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Feb 2011

Primary completion

Feb 2012

Study completion Jun 2012

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Astellas Pharma Inc
First posted
Jun 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Blockage of the heart arteries (coronary artery disease) can lead to angina (chest pain), heart attacks, heart failure, and/or death. Positron emission tomography (PET) stress myocardial perfusion imaging (MPI) is a powerful tool to help identify blockages in the coronary arteries. During the PET MPI test, a drug is given to mimic the effects of exercise on the heart. The study was done to measure blood flow to the heart using two similar drugs approved to mimic the effects of exercise on the heart in people during a heart stress test. The first drug, called adenosine, has been approved for this use for several decades. The second drug, called regadenoson, was approved in 2008. The investigators were looking at whether the increase in blood flow to the heart with the newer drug (regadenoson) was similar to the increase in blood flow with the older drug (adenosine). This information is important for the use of these drugs in patients and for interpreting the blood flow values.

Conditions

  • Coronary Artery Disease

Interventions

  • RegadenosonDrug

    Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.

  • AdenosineDrug

    Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.

  • N-13 ammoniaDrug

    Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global Hyperemic Myocardial Blood Flow (MBF)Time frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.